

DG SANTE INTERNAL DOCUMENT - NOT FOR FURTHER CIRCULATION

Table 1. Proposed selection of vaccine candidates

	Platform	Type of candidate vaccine	Developer	Status of the trials	Same platform for non-Coronavirus candidates
Candidate Vaccine 1	Non-Replicating Viral Vector	Ad26 (alone or with MVA boost)	Janssen Pharmaceutical Companies	Pre-Clinical	Ebola, HIV, RSV
Candidate Vaccine 2	DNA	DNA plasmid vaccine Electroporation device	Inovio Pharmaceuticals	Clinical Phase 1	
Candidate vaccine 3	RNA	LNP-encapsulated mRNA	Moderna/NIAID	Clinical Phase 1	
Candidate vaccine 4	RNA	mRNA	Curevac	Pre-Clinical	
Candidate vaccine 5	RNA	mRNA	BioNTech/Fosun Pharma/Pfizer	Clinical Phase 1	
Candidate vaccine 6	Protein Subunit	S protein	Sanofi Pasteur/GSK	Pre-Clinical	Influenza, SARS-CoV
Candidate vaccine 7	Inactivated and purified complete virus	purified inactivated SARS-CoV-2 virus vaccine candidate + alum	Sinovac Biotech in collaboration with several Chinese Universities and Institutes	Clinical Phase 1	SARS
Candidate vaccine 8	Replicating Viral Vector	Measles Vector	Institute Pasteur/Themis/Univ. of Pittsburg Center for Vaccine Research	Pre-Clinical	West nile, chik, Ebola, Lassa, Zika
Candidate vaccine 9	Non-Replicating Viral Vector	ChAdOx1	University of Oxford	Clinical Phase 1	MERS, influenza, TB, Chikungunya, Zika, MenB, plague

This is not a list that EMA has established according to a set of selection criteria nor is it a reflection of any prioritisation of the listed vaccines by EMA.